Review article: rifabutin in the treatment of refractory Helicobacter pylori infection

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Alimentary Pharmacology and Therapeutics

• Publication date

  2012-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2036.2011.04937.xPMID 22129228
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clarithromycin

  2012cited by this paper
• Rifabutin

  2012cited by this paper
• Basis for the Management of Drug-Resistant Helicobacter pylori Infection

  2012cited by this paper
• Review article: non‐bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori

  2011cited by this paper
• Helicobacter pylori isolates from proximal and distal stomach of patients never treated and already treated show genetic variability and discordant antibiotic resistance

  2011cited by this paper
• High Helicobacter pylori Resistance to Metronidazole but Zero or Low Resistance to Clarithromycin, Levofloxacin, and Other Antibiotics in Malaysia

  2011cited by this paper
• Is culture necessary before first-line treatment for Helicobacter pylori infection?

  2011cited by this paper
• Sequential Therapy for Helicobacter pylori Eradication: A Critical Review

  2010cited by this paper
• Clinical practice. Helicobacter pylori infection.

  2010cited by this paper
• Worldwide H. pylori antibiotic resistance: a systematic review.

  2010cited by this paper
• Treatment of Helicobacter pylori Infection 2010

  2010cited by this paper
• Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis

  2010cited by this paper
• Helicobacter pylori Infection REPLY

  2010cited by this paper
• Efficacy of four different moxifloxacin-based triple therapies for first-line H. pylori treatment.

  2010cited by this paper
• Second-line and rescue therapies for Helicobacter pylori eradication in clinical practice.

  2010cited by this paper
• Rescue therapy using a rifabutin-based regimen is effective for cure of Helicobacter pylori infection.

  2010cited by this paper
• Frequency and molecular characteristics of ciprofloxacin- and rifampicin-resistant Helicobacter pylori from gastric infections in the UK.

  2009cited by this paper
• Efficacy of triple therapy with a proton pump inhibitor, levofloxacin, and amoxicillin as first-line treatment to eradicate Helicobacter pylori.

  2009cited by this paper
• Past Rifampicin Dosing Determines Rifabutin Resistance of Helicobacter pylori

  2009cited by this paper
• One‐Week Once‐Daily Triple Therapy with Esomeprazole, Moxifloxacin, and Rifabutin for Eradication of Persistent Helicobacter pylori Resistant to Both Metronidazole and Clarithromycin

  2008cited by this paper
• A Report on the International Transglutaminase Autoantibody Workshop for Celiac Disease

  2008cited by this paper
• Treatment of Helicobacter pylori infection

  2008cited by this paper
• Emerging Therapies for the Treatment of Helicobacter pylori Infections

  2008cited by this paper
• "Cervia II Working Group Report 2006": guidelines on diagnosis and treatment of Helicobacter pylori infection in Italy.

  2007cited by this paper
• Characterization of rifampicin-resistant clinical Helicobacter pylori isolates from Germany.

  2007influential reference
• The effectiveness of rifabutin triple therapy for patients with difficult‐to‐eradicate Helicobacter pylori in clinical practice

  2007influential reference
• Efficacy of rifabutin‐based triple therapy in Helicobacter pylori infected patients after two standard treatments

  2007cited by this paper
• Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate helicobacter pylori infection

  2007influential reference
• Empirical rescue therapy after Helicobacter pylori treatment failure: a 10‐year single‐centre study of 500 patients

  2007cited by this paper
• American College of Gastroenterology Guideline on the Management of Helicobacter pylori Infection

  2007cited by this paper
• A Report Card to Grade Helicobacter pylori Therapy

  2007cited by this paper
• Role of the Preliminary Susceptibility Testing for Initial and After Failed Therapy of Helicobacter pylori Infection with Levofloxacin, Amoxicillin, and Esomeprazole

  2006cited by this paper
• Third‐line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures

  2006cited by this paper
• Treatment of Helicobacter pylori Infection

  2006cited by this paper
• Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis.

  2006cited by this paper
• Analysis of genetic variability, antimicrobial susceptibility and virulence markers in Helicobacter pylori identified in Central Italy

  2006influential reference
• Systematic review and meta‐analysis: levofloxacin‐based rescue regimens after Helicobacter pylori treatment failure

  2006cited by this paper
• Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report

  2006cited by this paper
• Efficacy and safety of rifabutin‐containing ‘rescue therapy’ for resistant Helicobacter pylori infection

  2006influential reference
• Levofloxacin-Based Triple Therapy versus Bismuth-Based Quadruple Therapy for Persistent Helicobacter pylori Infection: A Meta-Analysis

  2006cited by this paper
• Randomized trial of rifabutin‐based triple therapy and high‐dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin

  2006influential reference
• Rifabutin‐ and furazolidone‐based Helicobacter pylori eradication therapies after failure of standard first‐ and second‐line eradication attempts in dyspepsia patients

  2005cited by this paper
• Helicobacter pylori“Rescue” Therapy After Failure of Two Eradication Treatments

  2005cited by this paper
• Rifabutin-Associated Panuveitis with Retinal Vasculitis in Pulmonary Tuberculosis

  2005cited by this paper
• [Eradication treatment of Helicobacter pylori. Recommendations of the II Spanish Consensus Conference].

  2005cited by this paper
• Rifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycin.

  2005cited by this paper
• Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000.

  2005cited by this paper
• Empirical Helicobacter pylori "rescue" therapy after failure of two eradication treatments.

  2004cited by this paper
• Treatment options for patients with Helicobacter pylori infection resistant to one or more eradication attempts.

  2004cited by this paper
• H pylori antibiotic resistance: prevalence, importance, and advances in testing

  2004cited by this paper
• Seven‐day therapy for Helicobacter pylori in the United States

  2004cited by this paper
• ‘Rescue’ Therapy with Rifabutin after Multiple Helicobacter pylori Treatment Failures

  2003cited by this paper
• Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second‐line treatment for Helicobacter pylori infection

  2003cited by this paper
• Mixed‐Infection of Antibiotic Susceptible and Resistant Helicobacter pylori Isolates in a Single Patient and Underestimation of Antimicrobial Susceptibility Testing

  2003cited by this paper
• Review article: the treatment of refractory Helicobacter pylori infection

  2003cited by this paper
• Detection of Rifabutin Resistance and Association of rpoB Mutations with Resistance to Four Rifamycin Derivatives in Helicobacter pylori

  2002cited by this paper
• Helicobacter pylori ‘rescue’ regimen when proton pump inhibitor‐based triple therapies fail

  2002cited by this paper
• A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole

  2001cited by this paper
• A triple therapy regimen after failed Helicobacter pylori treatments

  2001cited by this paper
• Rifabutin‐based Helicobacter pylori eradication ‘rescue therapy’

  2001cited by this paper
• Efficacy of Helicobacter pylori eradication therapies: a single centre observational study

  2001influential reference
• In Vitro Activity of Clarithromycin against Intracellular Helicobacter pylori

  2001cited by this paper
• Randomized study of two “rescue” therapies for helicobacter pylori-infected patients after failure of standard triple therapies

  2001cited by this paper
• Alternative antibacterial agents for Helicobacter pylori eradication

  2001cited by this paper
• Helicobacter pylori Therapy: First-Line Options and Rescue Regimen

  2001cited by this paper
• Efficacy of a multistep strategy for Helicobacter pylori eradication

  2000cited by this paper
• Mutations in the Beginning of the rpoBGene Can Induce Resistance to Rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis

  2000cited by this paper
• Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicenter, double-blind trials

  2000cited by this paper
• Cure of Helicobacter pylori infection after failed primary treatment: one-center results from 120 patients.

  2000cited by this paper
• Treatment of Helicobacter pylori infection

  2000cited by this paper
• Rifabutin-based Triple Therapy After Failure of Helicobacter pylori Eradication Treatment: Preliminary Experience

  2000cited by this paper
• Regular review: treatment of Helicobacter pylori infection.

  2000cited by this paper
• Third line treatment for Helicobacter pylori: a prospective, culture‐guided study in peptic ulcer patients

  2000cited by this paper
• Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate‐based therapies

  2000cited by this paper
• In vitro activity of rifabutin against strains of Helicobacter pylori resistant to metronidazole and clarithromycin

  2000cited by this paper
• Rifabutin‐based ‘rescue therapy’ for Helicobacter pylori infected patients after failure of standard regimens

  2000cited by this paper
• Rifampin and Rifabutin Resistance Mechanism inHelicobacter pylori

  1999cited by this paper
• In Vitro Anti-Helicobacter pyloriActivities of New Rifamycin Derivatives, KRM-1648 and KRM-1657

  1999cited by this paper
• Evaluation of treatment regimens to cure Helicobacter pylori infection—a meta‐analysis

  1999cited by this paper
• Simultaneous colonisation of Helicobacter pylori with and without mutations in the 23S rRNA gene in patients with no history of clarithromycin exposure

  1999cited by this paper
• [An update on the antibiotic therapy of tuberculosis].

  1999cited by this paper
• [Asia Pacific Consensus Conference on the management of Helicobacter pylori].

  1999cited by this paper
• Treatment of antibiotic-resistant Helicobacter pylori.

  1998cited by this paper
• Treatment of Helicobacter pylori infection.

  1998cited by this paper
• Clinical Relevance of resistant strains of Helicobacter pylori: a review of current data

  1998cited by this paper
• Antibiotic resistance in Helicobacter pylori : Implications for therapy

  1998cited by this paper
• Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection

  1998cited by this paper
• Antibiotic resistance in Helicobacter pylori: implications for therapy.

  1998cited by this paper
• Guidelines for the management of Helicobacter pylori infection

  1998cited by this paper
• The use of rifabutin in Europe for the treatment of mycobacterial infection in AIDS patients

  1997cited by this paper
• Metabolism of rifabutin in human enterocyte and liver microsomes: Kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents

  1997cited by this paper
• Severe neutropenia caused by recommended prophylactic doses of rifabutin.

  1996cited by this paper
• Antimicrobial activity of rifabutin.

  1996influential reference
• Clinical pharmacokinetics of rifabutin.

  1996cited by this paper
• In vivo disposition and metabolism by liver and enterocyte microsomes of the antitubercular drug rifabutin in rats.

  1996cited by this paper
• Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease.

  1995cited by this paper
• Clinical Pharmacokinetics of Rifabutin

  1995cited by this paper
• Overview of toxicological data on rifabutin.

  1995cited by this paper
• Rifabutin: A Review with Emphasis on its Role in the Prevention of Disseminated Mycobacterium Avium Complex Infection

  1994cited by this paper

• Targeting Helicobacter pylori enzymes using Viscum album L. extract: in silico molecular docking and in vitro study

  2026cites this paper
• Third-Line and Later Susceptibility-Guided Helicobacter pylori Eradication Therapies: A Multicenter Study of Vonoprazan–Amoxicillin–Sitafloxacin/Rifabutin Regimens

  2026cites this paper
• Rifabutin-Containing Therapy for Helicobacter pylori Eradication: A Review.

  2025cites this paper
• Efficacy of Rifabutin‐Based Helicobacter pylori Eradication Regimen in Korea With High Prevalence of Tuberculosis Infection

  2025cites this paper
• Efficacy of a 7-day vonoprazan, sitafloxacin, and amoxicillin triple therapy as a fourth-line salvage regimen for refractory Helicobacter pylori infection

  2025cites this paper
• Insights on prevention and gastric cancer detection: an integrative approach through risk factors, microbiome, molecular markers and machine learning

  2025cites this paper
• Superior Efficacy of Bismuth-Containing Rifabutin Quadruple Therapy over Rifabutin Triple Therapy as Salvage Treatment

  2025cites this paper
• Whole genome sequence analysis of Helicobacter pylori isolates reveals incomplete characterization of antimicrobial resistance mechanisms

  2025cites this paper
• Empirical Rescue Eradication Therapy for Helicobacter pylori Infection in Second and Subsequent Treatment Lines: Experience From 500 Cases of the Brazilian Registry on H. pylori Management (Hp‐BrazilReg)

  2025influential citation
• Antimicrobial Resistance Patterns of Clinical Helicobacter pylori Isolates From Gastric Cancer Patients.

  2025cites this paper
• Antibiotic susceptibility pattern of Helicobacter pylori against eight antibiotics: A study from North India

  2024cites this paper
• Antibiotic Resistance of Helicobacter pylori: Mechanisms and Clinical Implications

  2024cites this paper
• An African perspective of Helicobacter pylori infection: A narrative review

  2024cites this paper
• Peptic ulcer disease.

  2024cites this paper
• Safety, pharmacokinetics, and efficacy of rifasutenizol, a novel dual-targeted antibacterial agent in healthy participants and patients in China with Helicobacter pylori infection: four randomised clinical trials.

  2024cites this paper
• Newer Therapies for Refractory Helicobacter pylori Infection in Adults: A Systematic Review

  2024cites this paper
• Helicobacter pylori, helicobacteriosis and associated diseases (VIII Moscow Agreements on the diagnosis and treatment of helicobacteriosis in adults and children) A Clinical Guide for Physicians

  2024cites this paper
• PREVALENCE AND RISK FACTORS OF HELICOBACTER PYLORI INFECTION AMONG INDIVIDUALS WITH TOBACCO CONSUMPTION HABITS IN DISTRICT PESHAWAR: A CROSS-SECTIONAL STUDY

  2023cites this paper
• Modern approaches to the treatment of peptic ulcer disease and prospects for the use of biological therapy

  2023cites this paper
• Modern approaches to the treatment of peptic ulcer disease and prospects for the use of biological therapy

  2023cites this paper
• EPIDEMIOLOGICAL STUDIES IN THE TREATMENT OF PEPTIC ULCER DISEASE

  2023cites this paper
• Diagnostic and therapeutic recommendations on Helicobacter pylori infection. Recommendations of the Working Group of the Polish Society of Gastroenterology

  2023cites this paper
• Consensus recommendations for the screening, diagnosis, and management of Helicobacter pylori infection in Hong Kong.

  2023cites this paper
• Exploring Alternative Treatment Choices for Multidrug-Resistant Clinical Strains of Helicobacter pylori in Mongolia

  2023cites this paper
• Rifabutin-containing Triple Therapy versus Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Multicenter, Randomized Controlled Trial.

  2023cites this paper
• First approach for the voltammetric sensing of rifabutin by the use of cationic surfactant media on the boron-doped diamond electrode

  2022cites this paper
• Need for standardization and harmonization of Helicobacter pylori antimicrobial susceptibility testing

  2022cites this paper
• Efficacy and safety of low‐dose rifabutin‐based 7‐day triple therapy as a third‐ or later‐line Helicobacter pylori eradication regimen

  2022cites this paper
• Helicobacter pylori Infection, Its Laboratory Diagnosis, and Antimicrobial Resistance: a Perspective of Clinical Relevance

  2022cites this paper
• Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg)

  2022cites this paper
• The Inappropriateness of Using Rifampicin E-Test to Predict Rifabutin Resistance in Helicobacter pylori.

  2022cites this paper
• Effectiveness and Safety of Rifaximin-Containing Regimens for Helicobacter pylori Eradication: Systematic Review – Are They Potential Eradication Regimens?

  2022cites this paper
• Salvage Regimens after Failure of Previous Helicobacter pylori Eradication Therapy: A Systematic Review and Meta-analysis

  2021cites this paper
• V Spanish Consensus Conference on Helicobacter pylori infection treatment.

  2021cites this paper
• Comments regarding use of rifabutin for Helicobacter pylori eradication

  2021cites this paper
• Revisiting Therapeutic Strategies for H. pylori Treatment in the Context of Antibiotic Resistance: Focus on Alternative and Complementary Therapies

  2021cites this paper
• Role of Antimicrobial Susceptibility Testing before First-Line Treatment Containing Clarithromycin for Helicobacter pylori Eradication in the Clinical Setting

  2021cites this paper
• V Spanish Consensus Conference on Helicobacter pylori infection treatment.

  2021cites this paper
• Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea 2020

  2021cites this paper
• AGA Clinical Practice Update on The Management of Refractory Helicobacter pylori Infection: Expert Review

  2021cites this paper
• Estrategias terapéuticas para Helicobacter pylori en Colombia

  2021cites this paper
• Treatment of Helicobacter pylori infection in the presence of penicillin allergy

  2021cites this paper
• H.pylori, part II: management in an era of antibiotic resistance

  2021cites this paper
• Evidence based guidelines for the treatment of Helicobacter pylori infection in Korea 2020

  2021cites this paper
• Probiotics as the live microscopic fighters against Helicobacter pylori gastric infections

  2021cites this paper
• Antibiotic Resistance of Helicobacter pylori Strains Isolated From Pediatric Patients in Southwest China

  2021cites this paper
• Management of Helicobacter pylori Infection: A Comparison between Korea and the United States

  2021cites this paper
• Pharmacology, Dosing, and Side Effects of Rifabutin as a Possible Therapy for Antibiotic-Resistant Acinetobacter Infections

  2020influential citation
• Rifabutin triple therapy for first‐line and rescue treatment of Helicobacter pylori infection: A systematic review and meta‐analysis

  2020cites this paper
• Helicobacter pylori treatment in the post-antibiotics era—searching for new drug targets

  2020cites this paper
• Update on the Management of Helicobacter pylori Infection

  2020cites this paper
• Best Helicobacter pylori Eradication Strategy in the Era of Antibiotic Resistance

  2020influential citation
• Rifamycin use for treatment of Helicobacter pylori infection: a review of recent data.

  2020cites this paper
• Rifabutin-Containing Triple Therapy (RHB-105) for Eradication of Helicobacter pylori: Randomized ERADICATE Hp Trial

  2020cites this paper
• Rifabutin-Based Triple Therapy Or Bismuth-Based Quadruple Regimen As Rescue Therapies For Helicobacter pylori Infection.

  2020cites this paper
• Resistance patterns of refractory Helicobacter pylori infection in a referral centre in the Delaware Valley

  2020cites this paper
• Helicobacter pylori first‐line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management (Hp‐EuReg)

  2020cites this paper
• Helicobacter pylori: A Review of Current Diagnostic and Management Strategies

  2020cites this paper
• Efficacy and safety of a new rifabutin‐based triple therapy with vonoprazan for refractory Helicobacter pylori infection: A prospective single‐arm study

  2020cites this paper
• Tratamiento y manejo de la infección por Helicobacter pylori

  2020cites this paper
• Rifabutin-Based Triple Therapy (RHB-105) for Helicobacter pylori Eradication

  2020cites this paper
• Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea: 2020 Revised Edition

  2020cites this paper
• Empirical or susceptibility-guided treatment for Helicobacter pylori infection? A comprehensive review

  2020cites this paper
• Rifabutin for the Treatment of Helicobacter pylori Infection: A Review

  2020cites this paper
• Rescue therapy with rifabutin regimen for refractory Helicobacter pylori infection with dual drug-resistant strain

  2020cites this paper
• Hellenic consensus on Helicobacter pylori infection

  2020cites this paper
• Rescue therapy with rifabutin regimen for refractory Helicobacter pylori infection with dual drug-resistant strains

  2020cites this paper
• Peptic Ulcer Disease: A Brief Review of Conventional Therapy and Herbal Treatment Options

  2019cites this paper
• Rifabutin-Based Rescue Therapy for Helicobacter pylori Eradication: A Long-Term Prospective Study in a Large Cohort of Difficult-to-Treat Patients

  2019influential citation
• Intraluminal therapy for Helicobacter pylori infection

  2019cites this paper
• Effective therapeutic regimens in two South Asian countries with high resistance to major Helicobacter pylori antibiotics

  2019cites this paper
• Are probiotics useful for therapy of Helicobacter pylori diseases?

  2019cites this paper
• Helicobacter pylori: ¿Cómo tratarla en América Latina en el 2019?

  2019cites this paper
• Prevalence of Helicobacter Pylori Infection in Patients with Upper Gastrointestinal Bleeding

  2019cites this paper
• Alternative eradication regimens for Helicobacter pylori infection in Indonesian regions with high metronidazole and levofloxacin resistance

  2019cites this paper
• Reconciliation of Recent Helicobacter pylori Treatment Guidelines in a Time of Increasing Resistance to Antibiotics.

  2019cites this paper
• Empirical Helicobacter pylori rescue therapy: an 18‐year single‐centre study of 1200 patients

  2019cites this paper
• How can Helicobacter pylori eradication therapies be improved ?

  2019cites this paper
• 10-Year Trends in Helicobacter pylori Eradication Rates by Sitafloxacin-Based Third-Line Rescue Therapy

  2019cites this paper
• Antibiotic interactions using liposomes as model lipid membranes.

  2019cites this paper
• Five alternative Helicobacter pylori antibiotics to counter high levofloxacin and metronidazole resistance in the Dominican Republic

  2019cites this paper
• Treatment of Helicobacter pylori infection: A clinical practice update

  2018cites this paper
• IVTH BRAZILIAN CONSENSUS CONFERENCE ON HELICOBACTER PYLORI INFECTION.

  2018cites this paper
• Helicobacter pylori Infection: An Update for the Internist in the Age of Increasing Global Antibiotic Resistance.

  2018cites this paper
• Helicobacter pylori: ¿cómo se trata en el 2018?

  2018cites this paper
• The efficacy of a 14-day modified quadruple therapy containing amoxicillin, tetracycline and high dose metronidazole and proton-pump inhibitors as an empirical third line helicobacter pylori eradication treatment in Taiwan

  2018cites this paper
• The Prevalence of Antibiotic Resistant Helicobacter pylori: A Literature Review

  2018cites this paper
• Helicobacter pylori antimicrobial resistance during a 5‐year period (2013‐2017) in northern Spain and its relationship with the eradication therapies

  2018cites this paper
• Efficacy of a 14-day quadruple-therapy regimen for third-line Helicobacter pylori eradication

  2018cites this paper
• Effective antimicrobial activity of rifabutin against multidrug‐resistant Helicobacter pylori

  2018cites this paper
• IVth Brazilian Consensus Conference on Helicobacter pylori infection

  2018cites this paper
• Pharmacological considerations and step-by-step proposal for the treatment of Helicobacter pylori infection in the year 2018.

  2018cites this paper
• Molecular characterization of Helicobacter pylori resistance to rifamycins

  2018cites this paper
• Current Status of the Third-Line Helicobacter pylori Eradication

  2018cites this paper
• [Helicobacter pylori: How do we treat it in 2018?]

  2018cites this paper
• Helicobacter pylori: ¿cómo mejorar las terapias de erradicación?

  2018cites this paper
• Helicobacter Pylori - a Worldwide Perspective 2014

  2018cites this paper
• Helicobacter pylori management in ASEAN: The Bangkok consensus report

  2018cites this paper
• deal treatment for Helicobacter pylori : A systematic review

  2017cites this paper
• World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat

  2017cites this paper